A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC

Clinical Trial ID NCT01957007

Rank	Title	Journal	Year	PubWeight™‹?›
1	Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.	Nat Rev Clin Oncol	2015	2.02
2	Molecular pathways and therapeutic targets in lung cancer.	Oncotarget	2014	1.16
3	Epithelial-mesenchymal transition: a new target in anticancer drug discovery.	Nat Rev Drug Discov	2016	0.98
4	Targeting the WNT Signaling Pathway in Cancer Therapeutics.	Oncologist	2015	0.92
5	NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.	Int J Cancer	2015	0.92
6	Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal.	Front Oncol	2016	0.80
7	The role of the Wnt signaling pathway in cancer stem cells: prospects for drug development.	Res Rep Biochem	2014	0.80
8	Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad.	Oxid Med Cell Longev	2016	0.78
9	Wnt/β-catenin pathway in tissue injury: roles in pathology and therapeutic opportunities for regeneration.	FASEB J	2016	0.77
10	Translational and clinical implications of the genetic landscape of prostate cancer.	Nat Rev Clin Oncol	2016	0.76